青光眼治疗方法的选择一直是国内外的热点，针对其病情进展缓慢和治疗过程持久的特点，特别是近年国外大量新药（局部降眼压药）的研制成功和投放市场，引发了学者们进入了一个新层次的探讨。鉴于这些新药已（将）不断进入中国和中国医疗体制的改革，有必要相应了解这些问题。 The selection of glaucoma treatment methods has always been a hot issue both at home and abroad. In view of its slow progression and long duration of treatment, especially in recent years a large number of new foreign drugs (topical intraocular pressure reducing agents) have been successfully developed and put on the market, prompting scholars to enter A new level of discussion. Given that these new drugs have (and will) continue to reform the health care system in China and China, it is necessary to understand these issues accordingly.